Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Satoru Torii has a total of 202 co-authors. Here are the top co-authors by number of shared publications:

  • Shigeomi Shimizu

    Institute of Science Tokyo

    19 shared publications
  • Shinya Honda

    Department of Pathological Cell Biology, Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kanda Surugadai, Chiyoda-ku, Tokyo, Japan

    12 shared publications
  • Hirofumi Yamaguchi

    Department of Pathological Cell Biology, Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, 2-3-10 Kanda Surugadai, Chiyoda-ku, Tokyo, Japan

    7 shared publications
  • Kazuhiro Sogawa

    Department of Biomolecular Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Japan

    7 shared publications
  • Satoko Arakawa

    Department of Pathological Cell Biology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

    7 shared publications
  • Ken-Ichi Yasumoto

    Department of Biomolecular Sciences, Graduate School of Life Sciences, Tohoku University, Aoba-ku, Sendai 980-8578, Japan

    6 shared publications

Latest Publications

  • Open Access

    Optineurin is an adaptor protein for ubiquitinated substrates in Golgi membrane-associated degradation

    by Yoichi Nibe-Shirakihara, Shinya Honda, Satoko Arakawa, Satoru Torii, Hajime Tajima Sakurai, Hirofumi Yamaguchi, Shigeru Oshima, Ryuichi Okamoto, Michael Lazarou, Hideshi Kawakami, et al.

    Golgi membrane-associated degradation (GOMED) is a process that leading to the degradation of proteins that have passed through the trans-Golgi membranes upon Golgi stress. GOMED is morphologically similar to autophagy, but the substrates degraded are different, and they thus have different biological roles. Although the substrate recognition mechanism of autophagy has been clarified in detail, that of GOMED is completely unknown. Here we report that GOMED degrades its substrate proteins selectively via optineurin (OPTN), as we found that the degradation of GOMED substrates is s`uppressed by the loss of OPTN. OPTN binds to K33 polyubiquitin-tagged proteins that have passed through the Golgi, which are then incorporated into GOMED structures for eventual degradation. In vivo, GOMED is known to be involved in the removal of mitochondria from erythrocytes, and in Optn-deficient mice, mitochondria are not degraded by GOMED, resulting in the appearance of erythrocytes containing mitochondria. These findings provide insight into the substrate recognition mechanism of GOMED.


  • Presence of Gut Microbiota Worsens D‐Galactosamine and Lipopolysaccharide‐Induced Hepatic Injury in Mice

    by Kazuma Ohshima, Satoru Torii, Shigeomi Shimizu

    Acute liver failure is a serious, life‐threatening disease. Although the gut microbiota has been considered to play a role in liver failure, the extent to which it is involved in the pathogenesis of this disease has not been fully elucidated to date. Therefore, we here analyzed the importance of the presence of intestinal microbiota in the pathogenesis of acute liver injury, using D‐galactosamine (D‐GalN)/lipopolysaccharide (LPS)‐treated mice, which is a widely used experimental model of acute liver injury. First, administration of the antibiotic polymyxin B markedly alleviated liver injury. Liver injury was also reduced in germ‐free mice, leading to the conclusion that the presence of intestinal microbiota aggravates D‐GalN/LPS‐induced liver injury. The amount of bacteria and LPS transferred from the gut to the blood was not increased by D‐GalN/LPS, suggesting that the worsening of liver injury was not simply owing to the entry of bacteria into the circulation. In conclusion, acute liver injury in polymyxin B‐pretreated or germ‐free mice was ameliorated by modulation of the gut microbiota. Modification of the gut microbiota using polymyxin B may hence have the potential to alleviate acute liver injury in human patients.


  • Open Access

    Photo-protective role of ATG5/ATG7-independent alternative autophagy in human keratinocytes

    by Tatsuya Hasegawa, Masaya Nakashima, Satoru Torii, Shinya Honda, Shigeomi Shimizu

    Excessive exposure to sunlight, especially to ultraviolet B (UVB), results in DNA damage and a cutaneous inflammatory reaction commonly known as sunburn, which increases skin cancer risks. UVB-induced inflammasome activation in epidermal keratinocytes mediates the cutaneous inflammatory response, but the intracellular machinery that maintains skin homeostasis by suppressing UVB-induced inflammasome activation is unclear. Here, we summarize our recent work on the protective role of alternative autophagy against UVB-induced NLRP3 (NLR family pyrin domain containing 3) inflammasome activation in human keratinocytes. We found that UVB radiation induces ATG5/ATG7-independent alternative (noncanonical) autophagy, which leads to suppression of NLRP3 inflammasome activation through the clearance of damaged mitochondria in UVB-irradiated keratinocytes. Our findings indicate that ATG5/ATG7-independent alternative autophagy, rather than conventional autophagy, may play a key role in mitigating inflammatory responses, and restoring skin homeostasis after UV radiation.

  • Open Access

    Alternative autophagy dampens UVB-induced NLRP3 inflammasome activation in human keratinocytes

    by Tatsuya Hasegawa, Saori Noguchi, Masaya Nakashima, Masashi Miyai, Makiko Goto, Yuko Matsumoto, Satoru Torii, Shinya Honda, Shigeomi Shimizu


  • Open Access

    Uncovering the Localization and Function of a Novel Read-Through Transcript ‘TOMM40-APOE’

    by Shichen Chang, Satoru Torii, Jun Inamo, Kinya Ishikawa, Yuta Kochi, Shigeomi Shimizu

    Recent advancements in genome analysis technology have revealed the presence of read-through transcripts in which transcription continues by skipping the polyA signal. We here identified and characterized a new read-through transcript, TOMM40-APOE. With cDNA amplification from THP-1 cells, the TOMM40-APOE3 product was successfully generated. We also generated TOMM40-APOE4, another isoform, by introducing point mutations. Notably, while APOE3 and APOE4 exhibited extracellular secretion, both TOMM40-APOE3 and TOMM40-APOE4 were localized exclusively to the mitochondria. But functionally, they did not affect mitochondrial membrane potential. Cell death induction studies illustrated increased cell death with TOMM40-APOE3 and TOMM40-APOE4, and we did not find any difference in cellular function between the two isoforms. These findings indicated that the new mitochondrial protein TOMM40-APOE has cell toxic ability.


  • Open Access

    An Overview of Golgi Membrane-Associated Degradation (GOMED) and Its Detection Methods

    by Hajime Tajima Sakurai, Satoko Arakawa, Hirofumi Yamaguchi, Satoru Torii, Shinya Honda, Shigeomi Shimizu

    Autophagy is a cellular mechanism that utilizes lysosomes to degrade its own components and is performed using Atg5 and other molecules originating from the endoplasmic reticulum membrane. On the other hand, we identified an alternative type of autophagy, namely, Golgi membrane-associated degradation (GOMED), which also utilizes lysosomes to degrade its own components, but does not use Atg5 originating from the Golgi membranes. The GOMED pathway involves Ulk1, Wipi3, Rab9, and other molecules, and plays crucial roles in a wide range of biological phenomena, such as the regulation of insulin secretion and neuronal maintenance. We here describe the overview of GOMED, methods to detect autophagy and GOMED, and to distinguish GOMED from autophagy.


  • Open Access

    An Overview of Golgi Membrane-Associated Degradation and Its Detection Methods

    by Hajime Tajima Sakurai, Satoko Arakawa, Hirofumi Yamaguchi, Satoru Torii, Shinya Honda, Shigeomi Shimizu

    Autophagy is a cellular mechanism that utilizes lysosomes to degrade its own components and is performed using Atg5 and other molecules originating from the endoplasmic reticulum membrane. On the other hand, we identified an alternative type of autophagy, namely, Golgi membrane-associated degradation (GOMED), which also utilizes lysosomes to degrade its own components, but does not use Atg5 originating from the Golgi membranes. The GOMED pathway involves Ulk1, Wipi3, Rab9 and other molecules, and plays crucial roles in a wide range of biological phenomena, such as the regulation of insulin secretion and neuronal maintenance. We here describe the overview of GOMED, the methods to detect autophagy and GOMED, and to distinguish GOMED from autophagy.

  • Open Access

    Involvement of casein kinase 1 epsilon/delta (Csnk1e/d) in the pathogenesis of familial Parkinson's disease caused by CHCHD2

    by Satoru Torii, Satoko Arakawa, Shigeto Sato, Kei‐Ichi Ishikawa, Daisuke Taniguchi, Hajime Tajima Sakurai, Shinya Honda, Yuuichi Hiraoka, Masaya Ono, Wado Akamatsu, et al.

    Parkinson's disease (PD) is a common neurodegenerative disorder that results from the loss of dopaminergic neurons. Mutations in coiled‐coil‐helix‐coiled‐coil‐helix domain containing 2 (CHCHD2) gene cause a familial form of PD with α‐Synuclein aggregation, and we here identified the pathogenesis of the T61I mutation, the most common disease‐causing mutation of CHCHD2. In Neuro2a cells, CHCHD2 is in mitochondria, whereas the T61I mutant (CHCHD2 T61I ) is mislocalized in the cytosol. CHCHD2 T61l then recruits casein kinase 1 epsilon/delta (Csnk1e/d), which phosphorylates neurofilament and α‐Synuclein, forming cytosolic aggresomes. In vivo , both Chchd2 T61I knock‐in and transgenic mice display neurodegenerative phenotypes and aggresomes containing Chchd2 T61I , Csnk1e/d, phospho‐α‐Synuclein, and phospho‐neurofilament in their dopaminergic neurons. Similar aggresomes were observed in a postmortem PD patient brain and dopaminergic neurons generated from patient‐derived iPS cells. Importantly, a Csnk1e/d inhibitor substantially suppressed the phosphorylation of neurofilament and α‐Synuclein. The Csnk1e/d inhibitor also suppressed the cellular damage in CHCHD2 T61I ‐expressing Neuro2a cells and dopaminergic neurons generated from patient‐derived iPS cells and improved the neurodegenerative phenotypes of Chchd2 T61I mutant mice. These results indicate that Csnk1e/d is involved in the pathogenesis of PD caused by the CHCHD2 T61I mutation.


  • Open Access

    ULK1-regulated AMP sensing by AMPK and its application for the treatment of chronic kidney disease

    by Tomoki Yanagi, Hiroaki Kikuchi, Koh Takeuchi, Koichiro Susa, Takayasu Mori, Naohiro Takahashi, Takefumi Suzuki, Yuta Nakano, Tamami Fujiki, Yu Hara, et al.

    AMP-activated protein kinase (AMPK) is a central kinase involved in energy homeostasis. Increased intracellular adenosine monophosphate (AMP) levels result in AMPK activation through the binding of AMP to the γ-subunit of AMPK. Recently, we reported that AMP-induced AMPK activation is impaired in the kidneys in chronic kidney disease (CKD) despite an increase in the AMP/ATP ratio. However, the mechanisms by which AMP sensing is disrupted in CKD are unclear. In this study, we identified mechanisms of energy homeostasis in which Unc-51-like kinase 1 (ULK1)-dependent phosphorylation of AMPKγ1 at Ser260/Thr262 promotes AMP sensitivity of AMPK. AMPK activation by AMP was impaired in Ulk1 −/− mice despite an increased AMP/ATP ratio. We also demonstrated that MK8722, an allosteric AMPK activator, activates AMPK in the kidneys of a CKD mouse model via a pathway that is independent of AMP sensing. MK8722 treatment significantly attenuates the deterioration of renal function in CKD and is a potential therapeutic option in CKD therapeutics.

  • Absence of ULK1 decreases AMPK activity in the kidney, leading to chronic kidney disease progression

    by Tomoki Yanagi, Hiroaki Kikuchi, Koichiro Susa, Naohiro Takahashi, Hiroki Bamba, Takefumi Suzuki, Yuta Nakano, Tamami Fujiki, Yutaro Mori, Fumiaki Ando, et al.

    AMP‐activated protein kinase (AMPK) inactivation in chronic kidney disease (CKD) leads to energy status deterioration in the kidney, constituting the vicious cycle of CKD exacerbation. Unc‐51‐like kinase 1 (ULK1) is considered a downstream molecule of AMPK; however, it was recently reported that the activity of AMPK could be regulated by ULK1 conversely. We demonstrated that AMPK and ULK1 activities were decreased in the kidneys of CKD mice. However, whether and how ULK1 is involved in the underlying mechanism of CKD exacerbation remains unknown. In this study, we investigated the ULK1 involvement in CKD, using ULK1 knockout mice. The CKD model of Ulk1−/− mice exhibited significantly exacerbated renal function and worsening renal fibrosis. In the kidneys of the CKD model of Ulk1−/− mice, reduced AMPK and its downstream β‐oxidation could be observed, leading to an energy deficit of increased AMP/ATP ratio. In addition, AMPK signaling in the kidney was reduced in control Ulk1−/− mice with normal renal function compared to control wild‐type mice, suggesting that ULK1 deficiency suppressed AMPK activity in the kidney. This study is the first to present ULK1 as a novel therapeutic target for CKD treatment, which regulates AMPK activity in the kidney.